Emend capsules combi-packing 3 capsules — Made in Netherlands — Free Delivery

Brand: MERCK
Product Code: Emend
Availability: In Stock

$144.31

Add to Cart

Description

Product description

Emend capsules combi-packing 3 pcs: 125 mg capsules 1 pc + 80 mg capsules 2 pcs in blisters

Emend® capsules are used in combination therapy:

prevention of acute and delayed nausea and vomiting associated with anti-cancer chemotherapy based on cisplatin with a high emetogenic risk in adults,
prevention of nausea and vomiting associated with the use of anticancer chemotherapy with moderate emetogenic risk in adults.

Compound

The active ingredient is aprepitant (one capsule contains 80 mg or 125 mg of aprepitant).

Excipients: sucrose, microcrystalline cellulose, hydroxypropyl cellulose, sodium lauryl sulfate.

The capsule shell is gelatin, titanium dioxide (E 171).

The 125 mg capsule shell also contains red iron oxide (E 172) and yellow iron oxide (E 172).

Contraindications

The preparation is contraindicated in patients with hypersensitivity to the components of the preparation.

Emend® should not be used concomitantly with pimozide, terfenadine, astemizole and cisapride.

Mode of application

Use "Emend®" for 3 days as part of a regimen that includes GCS and a 5-HT3 antagonist. The recommended dose of Emend® is 125 mg orally (po) 1 hour before chemotherapy (on the 1st day) and 80 mg once a day in the morning (on the 2nd and 3rd days).

The following treatment regimens are recommended for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy.

High emetogenic risk chemotherapy course:

"Emend®":

day 1 - 125 mg p / o;
day 2 - 80 mg p / o;
day 3 - 80 mg p / o;
day 4 - no;

dexamethasone:

day 1 - 12 mg p / o;
day 2 - 8 mg p / o;
day 3 - 8 mg p / o;
day 4 - 8 mg p / o;

5-HT3 antagonist:

day 1 - standard dose of 5-HT3 antagonist;
day 2 - no;
day 3 - no;
day 4 - no.

Dexamethasone should be used 30 minutes before chemotherapy on day 1 and in the morning from day 2 to day 4. The dose of dexamethasone was chosen based on preparation interactions.

Moderate emetogenic risk chemotherapy course:

"Emend®":

day 1 - 125 mg p / o;
day 2 - 80 mg p / o;
day 3 - 80 mg p / o;

dexamethasone:

day 1 - 12 mg p / o;
day 2 - no;
day 3 - no;

5-HT3 antagonist:

day 1 - standard dose of 5-HT3 antagonist;
day 2 - no;
day 3 - no.

Dexamethasone should be used 30 minutes before chemotherapy on day 1. The dose of dexamethasone was chosen based on preparation interactions.

Limited data on the effectiveness of the combination with other corticosteroids and 5-HT3 antagonists.

Application features

Pregnant

The preparation should not be used during pregnancy, unless absolutely necessary.

During treatment with Emend®, breastfeeding is not recommended.

The potential for the effect of aprepitant on fertility is not fully understood because exposure levels in excess of therapeutic exposure in humans cannot be achieved in animal studies. Fertility studies have not demonstrated direct or indirect adverse effects on mating, fertility, embryo / fetal development, or sperm count and motility.

Children

The safety and efficacy of using the Emend® preparation for the treatment of children and adolescents under the age of 18 have not been established. There are no data, therefore, the preparation is not recommended for use in such patients.

Drivers

The preparation "Emend®" may slightly affect the ability to drive vehicles and mechanisms. After using the preparation, dizziness and fatigue may occur.

Overdose

In case of overdose, you should stop taking the preparation "Emend®" and prescribe general supportive therapy, as well as provide monitoring. Because of the antiemetic activity of aprepitant, preparations that induce vomiting will be ineffective. Aprepitant cannot be removed by hemodialysis.

Side effects

In patients treated with aprepitant during chemotherapy with a high risk of emetogenicity, the following adverse reactions most often occurred due to taking the drug: hiccups (4.6%), increased ALT levels (2.8%), dyspepsia (2.6%), constipation (2.4%), headache (2.0%), loss of appetite (2.0%). During chemotherapy with a moderate risk of emetogenicity, increased fatigue most often occurred (1.4%).

Storage conditions

Store in its original packaging at a temperature not exceeding 30 ° C, out of the reach of children and protected from moisture.

Shelf life is 4 years.

0 reviews

There are no reviews for this product.